Gujarat Kidney and Super Speciality Limited (GKSSL) has submitted its Q2 FY27 Investor Presentation to BSE and NSE under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation discloses unaudited consolidated results for the quarter and half year ended 30 September 2026, which have undergone limited review by the statutory auditor.

Financial Performance Q2 FY27 (₹ in Lakhs)

  • Revenue from Operations: ₹3,809, representing +11.1% QoQ growth and +194.6% YoY growth
  • Other Income: ₹59 (-14.8% QoQ, +567.5% YoY)
  • Total Income: ₹3,868 (+10.6% QoQ, +197.1% YoY)
  • Gross Profit: ₹3,334 at 87.5% margin (+11.3% QoQ, +186.7% YoY)
  • Employee Cost: ₹777 (+47.0% QoQ, +249.0% YoY)
  • Other Expenses: ₹1,535 (-5.7% QoQ, +258.8% YoY)
  • EBITDA: ₹1,022 at 26.8% margin (+22.0% QoQ, +99.4% YoY)
  • PAT: ₹660 at 17.3% margin (+24.0% QoQ, +129.4% YoY)

Financial Performance H1 FY27 (₹ in Lakhs)

  • Revenue from Operations: ₹7,238 (+156.8% YoY), representing 88% of FY26 full-year revenue
  • Other Income: ₹128 (Not Meaningful comparison)
  • Cost of medical consumables, drugs and surgical items: ₹910 (+237.9% YoY)
  • Employee benefits expense: ₹1,306 (+203.0% YoY)
  • Finance costs: ₹132 (+186.5% YoY)
  • Depreciation and amortization expense: ₹296 (+58.7% YoY)
  • Other expenses: ₹3,164 (+325.2% YoY)
  • Profit After Tax: ₹1,192 (+44.0% YoY)
  • Total Comprehensive Income: ₹1,203 (+44.6% YoY)
  • Attributable to owners: ₹1,115 (+47.6% YoY)
  • Attributable to non-controlling interests: ₹88 (+15.1% YoY)

Balance Sheet Position as of 30-Sep-2026 (₹ in Lakhs)

  • Equity Share Capital: ₹1,577 (unchanged from Mar-26)
  • Other Equity: ₹24,787 (up from ₹23,674 at Mar-26)
  • Total Equity: ₹26,364
  • Non-controlling interests: ₹623 (up from ₹222 at Mar-26)
  • Cash and cash equivalents: ₹1,211
  • Bank balances: ₹2,007
  • Total Cash & Bank: ₹3,218
  • Borrowings: ₹1,729 (₹120 non-current, ₹1,610 current)
  • Lease liabilities: ₹1,297 (₹1,205 non-current, ₹92 current)
  • Net cash position: ₹1,488 (excluding leases)
  • Goodwill: ₹10,742 (up from ₹9,073 at Mar-26)
  • Property, Plant and Equipment: ₹3,193
  • Right of Use Assets: ₹1,010
  • Investments: ₹1,200 (new from Mar-26)

Operational Metrics

  • H1 FY27 IPD Admissions: 11,040 (83% of FY26 full-year volumes)
  • H1 FY27 OPD Visits: 78,643 (82% of FY26 full-year volumes)
  • Bed Occupancy: ~55%
  • Average Length of Stay: ~6 days
  • Employee Count: 670 employees including 89 full-time and 238 visiting consultants (as of 09 November 2025)

Strategic Developments

  • Acquisition Activity: ₹1,669 lakhs deployed towards acquisitions in H1 FY27
  • Dubai Expansion: Acquired 51% stake in Blue Tree Clinics (Dubai polyclinic) with remaining 49% in process of acquisition
  • Dubai entity generated 5.1 Mn AED revenue from Jan'26-June'26 (approximately ₹20-25 Cr)
  • Strategic focus on medical tourism and international patient referral opportunities

Hospital Network

The company operates through a network of hospitals across Gujarat and Dubai:

  • Parekh Hospital, Ahmedabad (100% stake)
  • Ashwini Medical Centre, Anand (100% stake)
  • Surya Hospital, Borsad (90% stake)
  • Gujarat Kidney & Superspeciality Hospital, Vadodara (100% stake)
  • Gujarat Surgical Hospital, Vadodara (90% stake)
  • Gujarat Multispeciality Hospital, Godhra (100% stake)
  • Raj Palmland Hospital, Bharuch (51% stake)
  • Apex 1, Bharuch (100% stake)
  • Apex 2, Zadeshwar (100% stake)
  • Patel Multispeciality Hospital, Ankleshwar (51% stake)
  • Blue Tree Clinics, Dubai (51% stake)

Management and Leadership

Led by Dr. Pragnesh Yashwantsinh Bharpoda, Promoter and Managing Director, a reputed urologist with over a decade of experience. The board includes Dr. Bhartiben Pragnesh Bharpoda (Whole-time Director), Anitaben Yashvantsinh Bharpoda (Non-Executive Director), and three independent directors: Jagdishbhai Vinodchandra Thakkar, Dr. Udayan Maheshkant Kachchhi, and Dr. Kairavi Naimesh Shah.

Future Strategy

The company plans to continue its asset-light expansion model focusing on:

  • Value-accretive acquisitions and alliances in central Gujarat micro-markets
  • Implementation of integrated healthcare network with centralized procurement
  • Deployment of advanced medical technology including Stryker orthopaedic robot
  • Possible tie-ups with small nursing homes for diagnostic and operative support
  • Strengthening specialities across hospitals with focus on urology, nephrology, interventional cardiology, and oncology